Feed / MAZE

Maze Therapeutics, Inc.

MAZE

Healthcare · 29.44 +1.7% today

Partial group confirmationMarket checked 21 Aug, 15:55 GMT-4

Jodie situation report

Maze Therapeutics, Inc.'s move is being confirmed by its market group.

MAZE accounts for 7.2% of the group's measured movement across 5.6 effective names. raw member direction is mixed; 7 of 12 session-normalized paths align to the upside. Capital-flow agreement is 16%, so confirmation is not yet clean. No verified headline preceded the measured group move.

MOVE ANATOMY

Is this move genuinely shared?

Session-normalized 5m paths
Role in the moveAligned contributor#6 of 12 by movement share
Group movement share7.2%Absolute path energy—not portfolio weight
Relative path+1.62%aligned
Effective breadth5.6 / 12balanced
Relative alignment7/12upside path · 1 counter-moving
Capital-flow agreement16%not yet clean
SEQUENCE READ

GPCR, PRAX, RCUS moved materially before MAZE. MAZE crossed its material path threshold at 15:05 ET, 1395 minutes after the first measured mover. TYRA followed.

EVIDENCE COVERAGE

10 of 16 members in Clinical Biopharmaceuticals are active. 0 of 6 disclosed connections are confirming.

What would change this read
  • At least 11 of 16 durable members become active together.
  • Capital-flow agreement rises above 55%.
  • A filing-linked outsider such as NBIX begins moving with the group.

Invalidation: The live read weakens if participation falls to 5 of 16 members or fewer.

Watch this read

Who this business touches

The relationships behind MAZE

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

SGIOFFiling-linked namepartnerNov 6, 2025

Except for the one-time, nonrefundable upfront payments we received pursuant to the license agreements we entered into with several biotechnology companies in 2024, including the exclusive license agreement with Shionogi & Company, Ltd., or Shionogi, we expec…

HTGCHercules Capital, Inc.lenderMay 12, 2026

Total other income, net Total other income, net, primarily consists of interest income earned on our cash, cash equivalents and marketable securities and interest expense recognized on the loan and security agreement, or the Hercules Loan Agreement, with cert…

Depended on by

BMRNBioMarin Pharmaceutical Inc.competitorFeb 26, 2026

There is also potential competition from clinical stage product candidates developed by Agios Pharmaceuticals Inc., Jnana Therapeutics Inc.

Filing peers

No filing peers are available for this name yet.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 3 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

MAZE is currently a Leader in the organic co-movement group Clinical Biopharmaceuticals. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.